Japan Clears Bayer’s Nexavar As Kidney-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's drug authority gave its approval to the German drug maker Bayer for its Nexavar (sorafenib) for treating kidney cancer. The approval came less than a week after the agency gave the drug priority review for an indication as a liver-cancer treatment, an indication already approved in several other countries. The drug also is being tested for several other types of cancer, such as non-small cell lung cancer and for breast cancer. (Click here for more
|
Japan's drug authority gave its approval to the German drug maker Bayer for its Nexavar (sorafenib) for treating kidney cancer. The approval came less than a week after the agency gave the drug priority review for an indication as a liver-cancer treatment, an indication already approved in several other countries. The drug also is being tested for several other types of cancer, such as non-small cell lung cancer and for breast cancer. ( Click here for more ) "Bayer Gets Japan Approval For Kidney Cancer Drug" Reuters (U.K.) (1 /28/08) |